Scientific Technology and R&D

IMM01 + Bortezomib+ Dexamethasonum

ImmuneOnco obtained the IND approval for Phase Ib/IIa clinical trial from the State Food and Drug Administration in January 2023 to evaluate the combination therapy of IMM01 with bortezomib and dexamethasone in the treatment of MM.

0.084403s